Protagonist Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	82.91	-130.15	275.19	-78.96	-127.39	-125.55
Depreciation & Amortization	1.54	1.28	0.83	0.98	1.03	0.81
Stock-Based Compensation	49.82	45.97	37.55	29.29	24.2	16.4
Other Adjustments	-3.77	-5.64	-6.81	-2.04	1.79	3.79
Change in Receivables	-13.42	164.88	-155	-9.99	4.24	-0.92
Changes in Accounts Payable	0.21	3.72	0.84	-2.93	1.22	-3.22
Changes in Accrued Expenses	6.35	4.58	4.29	-5.6	-12.72	19.1
Changes in Income Taxes Payable	-	-2.69	2.69	-	-	-
Changes in Unearned Revenue	-10.4	-21.02	30.57	-	-1.6	-12.88
Changes in Other Operating Activities	-3.5	-3.26	-5.99	-0.99	1.09	-5.4
Operating Cash Flow	131.2	57.67	184.15	-70.24	-108.14	-107.87
Operating Cash Flow Growth	231.79%	-68.68%	-	-	-	-
Capital Expenditures	-0.62	-1.59	-1.36	-0.61	-0.8	-1.1
Purchases of Investments	-469.04	-546.59	-621.7	-191.05	-214.87	-286.59
Proceeds from Sale of Investments	548.37	498.84	323.57	152.4	307.14	271.83
Investing Cash Flow	78.72	-49.33	-299.48	-39.26	91.47	-15.86
Issuance of Common Stock	41.61	23.34	26.45	171.25	19	130.11
Repurchase of Common Stock	-	-0.48	-0.6	-0.77	-0.19	-0.19
Net Common Stock Issued (Repurchased)	41.61	22.86	25.85	170.48	18.81	129.92
Other Financing Activities	-	-	-	-	0.03	-
Financing Cash Flow	41.61	22.86	25.85	170.48	18.84	129.92
Foreign Exchange Rate Adjustments	-	-	-	-	-0.09	-0.13
Net Cash Flow	251.53	31.2	-89.48	60.98	2.08	6.07
Free Cash Flow	130.58	56.08	182.8	-70.85	-108.93	-108.97
Free Cash Flow Growth	251.98%	-69.32%	-	-	-	-
FCF Margin	46.31%	121.87%	42.08%	-118.08%	-409.81%	-398.31%
Free Cash Flow Per Share	1.94	0.88	2.81	-1.25	-2.22	-2.35
Levered Free Cash Flow	-45.75	-149.13	307.05	-88.11	-139.16	-128.24
Unlevered Free Cash Flow	48.63	-178.13	280.89	-102.81	-143.14	-128.53

SEC Filings: 10-K · 10-Q